Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Binnopharm Group","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Binnopharm Group Enters Into Agreement to Acquire Two Anti-Bacterial Brands From Dr. Reddy\u2019s in the Russia & CIS Region","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"RUSSIA","productType":"Small molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Binnopharm Group","sponsor":"Mabwell Bioscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mabwell Bioscience Partners with Binnopharm Group to Market 9MW0113, 9MW0321 and 9MW0311 in Russia and Eurasian Economic Union Countries","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"RUSSIA","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Binnopharm Group

    Menu

    Binnopharm Group

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Binnopharm Group

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Russia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Mabwell Bioscience Partners with Binnopharm Group to Market 9MW0113, 9MW0321 and 9MW0311 in Russia and Eurasian Economic Union Countries

              Details:

              Junmaikang (adalimumab) is a biosimilar of Humira, Junmaikang was approved in China for Rheumatoid arthritis, ankylosing spondylitis, Psoriasis, Crohn's disease, uveitis, polyarticular juvenile idiopathic arthritis and Crohn's disease in children.

              Lead Product(s): Adalimumab

              Therapeutic Area: Immunology Product Name: Junmaikang

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Mabwell Bioscience

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement December 20, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Binnopharm Group

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Russia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Binnopharm Group Enters Into Agreement to Acquire Two Anti-Bacterial Brands From Dr. Reddy’s in the Russia & CIS Region

              Details:

              Deal will allow Binnopharm Group to acquire anti-bacterial medicines under the Ciprolet® and Levolet® brands from Dr. Reddy’s in Russia, Uzbekistan and Belarus. The portfolio includes various dosage forms such as tablets, solution for infusions and eye drops.

              Lead Product(s): Ciprofloxacin

              Therapeutic Area: Infections and Infectious Diseases Product Name: Ciprolet

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Dr. Reddy\'s Laboratories

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition February 21, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY